Does NINTEDANIB Cause Tumour marker increased? 7 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 7 reports of Tumour marker increased have been filed in association with NINTEDANIB. This represents 0.0% of all adverse event reports for NINTEDANIB.
7
Reports of Tumour marker increased with NINTEDANIB
0.0%
of all NINTEDANIB reports
0
Deaths
4
Hospitalizations
How Dangerous Is Tumour marker increased From NINTEDANIB?
Of the 7 reports, 4 (57.1%) required hospitalization.
Is Tumour marker increased Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for NINTEDANIB. However, 7 reports have been filed with the FAERS database.
What Other Side Effects Does NINTEDANIB Cause?
Diarrhoea (9,103)
Nausea (4,198)
Dyspnoea (3,080)
Decreased appetite (2,832)
Death (2,790)
Weight decreased (2,628)
Vomiting (2,524)
Fatigue (2,511)
Cough (2,193)
Idiopathic pulmonary fibrosis (1,905)
What Other Drugs Cause Tumour marker increased?
PALBOCICLIB (817)
FULVESTRANT (408)
NIRAPARIB (356)
LETROZOLE (343)
RIBOCICLIB (317)
RUCAPARIB CAMSYLATE (257)
CAPECITABINE (228)
EVEROLIMUS (228)
ELACESTRANT (222)
OLAPARIB (171)
Which NINTEDANIB Alternatives Have Lower Tumour marker increased Risk?
NINTEDANIB vs NINTEDANIB ESYLATE
NINTEDANIB vs NIRAPARIB
NINTEDANIB vs NIRMATRELVIR\RITONAVIR
NINTEDANIB vs NIROGACESTAT
NINTEDANIB vs NIROGACESTAT HYDROBROMIDE